Education
About Us
Working with TipRanks
Follow Us
Stoke Therapeutics Inc (STOK)
NASDAQ:STOK
STOK Stock Chart & Stats
$33.78
-$0.34(-3.65%)
At close: 4:00 PM EST
$33.78
-$0.34(-3.65%)
Day’s Range― - ―
52-Week Range$5.35 - $39.81
Previous CloseN/A
Volume337.58K
Average Volume (3M)585.76K
Market Cap
$1.93B
Enterprise Value$1.87B
Total Cash (Recent Filing)$248.31M
Total Debt (Recent Filing)$2.91M
Price to Earnings (P/E)51.2
Beta1.69
Next Earnings
Mar 11, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding57,117,150
10 Day Avg. Volume657,748
30 Day Avg. Volume585,763
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.60
Price to Sales (P/S)16.30
P/FCF Ratio-6.84
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue9.11
Enterprise Value/Gross Profit9.15
Enterprise Value/Ebitda56.60
Forecast
1Y Price Target
$41.38Price Target Upside22.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.12
Revenue Forecast (FY)$26.25M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Disease ModificationZorevunersen has shown large seizure reductions along with accumulating cognitive and behavioral gains, suggesting the therapy may modify the underlying course of Dravet syndrome rather than only managing symptoms.
Pipeline Expansion And Orphan OpportunityDosing the first patient in the STK-002 Phase 1 study and orphan drug designation position a second TANGO-based program as a potential first disease-modifying treatment for a rare optic neuropathy, diversifying pipeline upside.
Regulatory Acceleration And TimelineFaster-than-expected enrollment in the Phase 3 EMPEROR study combined with a planned rolling regulatory submission could shorten the pathway to potential approval and improve visibility on commercial timing.
Bears Say
Limited Approval And Commercial ImpactA regulatory filing based on limited early data risks approval only for seizure control rather than disease modification, which would likely weaken pricing power and reduce market penetration.
Regulatory Data UncertaintyRegulators viewing a key efficacy analysis as post hoc and the FDA's request for additional Vineland-3 review create uncertainty around approval timing and raise the risk of volatile regulatory outcomes.
Safety And Tolerability Risk For STK-002Progression of STK-002 hinges on favorable safety, tolerability, and exposure findings, meaning adverse results could materially limit or delay program advancement.
Stoke Therapeutics News
STOK FAQ
What was Stoke Therapeutics Inc’s price range in the past 12 months?
Stoke Therapeutics Inc lowest stock price was $5.35 and its highest was $39.81 in the past 12 months.
What is Stoke Therapeutics Inc’s market cap?
Stoke Therapeutics Inc’s market cap is $1.93B.
When is Stoke Therapeutics Inc’s upcoming earnings report date?
Stoke Therapeutics Inc’s upcoming earnings report date is Mar 11, 2026 which is in 7 days.
How were Stoke Therapeutics Inc’s earnings last quarter?
Stoke Therapeutics Inc released its earnings results on Nov 04, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.568 by -$0.082.
Is Stoke Therapeutics Inc overvalued?
According to Wall Street analysts Stoke Therapeutics Inc’s price is currently Undervalued.
Does Stoke Therapeutics Inc pay dividends?
Stoke Therapeutics Inc does not currently pay dividends.
What is Stoke Therapeutics Inc’s EPS estimate?
Stoke Therapeutics Inc’s EPS estimate is -0.74.
How many shares outstanding does Stoke Therapeutics Inc have?
Stoke Therapeutics Inc has 57,117,150 shares outstanding.
What happened to Stoke Therapeutics Inc’s price movement after its last earnings report?
Stoke Therapeutics Inc reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.568. Following the earnings report the stock price went down -9.945%.
Which hedge fund is a major shareholder of Stoke Therapeutics Inc?
Currently, no hedge funds are holding shares in STOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stoke Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.38 (22.50% Upside)
$41.38 (22.50% Upside)
Blogger Sentiment
Bullish
STOK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 528.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
356.48%
12-Months-Change
Fundamentals
Return on Equity
15.02%
Trailing 12-Months
Asset Growth
22.82%
Trailing 12-Months
Company Description
Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
STOK Company Deck
STOK Earnings Call
Q3 2025
0:00 / 0:00
STOK Stock 12 Month Forecast
Average Price Target
$41.38
▲(22.50% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Xeris Pharmaceuticals
―
―
Rapport Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---